Iradimed vs Pulmonx
Iradimed and Pulmonx are similar in size: $83.8m and $90.5m of revenue in their latest fiscal years. Iradimed grew faster (14.4% against 8.0%). Iradimed kept more of each dollar of sales as profit: a net margin of 26.8% against -59.7%. Iradimed carries less debt relative to equity (0.0% against 78.5%).
| Latest fiscal year | IradimedIRMD, 2025 | PulmonxLUNG, 2025 |
|---|---|---|
| Revenue | $83.8m | $90.5m |
| Revenue growth | 14.4% | 8.0% |
| Net income | $22.5m | −$54.0m |
| Operating margin | 31.2% | -59.3% |
| Net margin | 26.8% | -59.7% |
| Return on equity | 24.8% | -77.2% |
| Free cash flow | $17.2m | −$32.8m |
| Cash | $51.2m | $69.8m |
| Total debt | $0 | $42.5m |
| Debt to equity | 0.0% | 78.5% |
| Dividend per share | — | — |
| Dividend yield | 1.6% | — |
| Share buybacks | — | — |
| Employees | — | 296 |
| Market value | $1.03bn | $114m |
| Price vs our value range | Above our value range | — |
| Moat score | 81 (Strong) | 35 (Weak) |
| Insider trades, 12 months | 0 buys, 116 sales | 0 buys, 55 sales |